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Introduction
Primaquine (PQ), an 8-amino-6-methoxyquinoline (8AQ) derivative is the only drug
approved by the United States Federal Drug Administration to treat acute illness and
relapse of Plasmodium vivax (P. vivax) and P. ovale infection caused by hypnozoites that
persist in the hepatocytes of infected patients.1,2 Recently, a number of studies reported
on the metabolism of PQ showing that biotransformation occurs through three main
pathways which are Cytochrome P450 (CYP450) enzymes (CYP2D6, CYP2C19,
CYP3A4, CYP1A2), monoamine oxidases (MAO-A and B) and ﬂavin-containing
monooxygenase-3 (FMO-3).3–7 PQ is a pro-drug primarily metabolized by MAO-A to
PQ aldehyde, which is further oxidized by aldehyde dehydrogenase (ADH) to carboxyprimaquine, the major PQ metabolite found in plasma.4,8 Carboxyprimaquine is further
oxidized by FMO to the N-hydroxylated PQ metabolite which can cause hemotoxicity.9
Finally, PQ is metabolized via CYP2D6 to 5-hydroxyprimaquine, 5, 6-orthoquinone, and
other phenolic metabolites; other P450 enzymes are also believed to contribute to PQ
1
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Purpose: Pharmacogenes have an inﬂuence on biotransformation pathway and clinical
outcome of primaquine and chloroquine which are often prescribed to treat Plasmodium
vivax infection. Genetic variation may impact enzyme activity and/or transporter function
and thereby contribute to relapse. The aim of the study was to assess allele, genotype
frequencies and the association between pharmacogenes variation and primaquine response
in Thai patients infected with Plasmodium vivax.
Patients and Methods: Fifty-one patients were genotyped for 74 variants in 18 genes by
Sequenom MassARRAY® and Taqman® SNP Real-Time PCR.
Results: SNP frequencies were not signiﬁcantly different between relapse (n=4) and nonrelapse (n=47) patients. However, the CYP2C19 c.681G>A, the frequency of the A-allele
that deﬁnes the non-functional CYP2C19*2 haplotype was signiﬁcantly higher compared to
the G-allele (OR=5.14, p=0.021). Patients heterozygous for ABCG2 c.421C>A had a higher
odds ratio (OR=8.75, p=0.071) and the frequency of the G-allele of UGT2B7 c.372G>A was
higher compared to the A-allele (OR=3.75, p=0.081). CYP2C19, ABCG2 and UGT2B7
emerged as potential high priority genes.
Conclusion: Decreased activity of CYP2C19, ABCG2 and UGT2B7 in combination with
CYP2D6 intermediate or poor metabolizer status may expose patients to a higher risk of
Plasmodium vivax relapse. Further investigations are warranted to substantiate these ﬁndings.
Keywords: primaquine, chloroquine, Plasmodium vivax, relapse, pharmacogenes
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metabolism.4,5,10 Chloroquine (CQ) is metabolized into
N-desethylchloroquine by CYP2C8, CYP3A4, and CYP2D6
by in vitro study.11
The major challenge of elimination of malaria caused
by P. vivax and P. ovale in endemic areas is relapse of
dormant hypnozoites that survive in the liver of the patient
after primary infection. These hypnozoites can persistent
in the liver for weeks, months or even years following
a primary attack.12,13 Although PQ has been used to treat
P. vivax and P. ovale infections for several decades, the
exact mechanisms of PQ efﬁcacy and toxicity are still not
well understood, neither have the metabolic pathways
been fully elucidated. It has been postulated that human
host genetics may, at least in part, contribute to the failure
of PQ treatment.7 Bennett et al7 ﬁrst reported a signiﬁcant
association between CYP2D6 metabolizer phenotype and
relapsing P. vivax infection. Relapsing CYP2D6 poor
(PM) and intermediate metabolizer (IM) patients had
a signiﬁcant higher plasma concentration of the parent
drug after 24 hrs compared to non-relapsing patients.
These data supported the hypothesis that the CYP2D6dependent pathway is crucial for the bioactivation of PQ
to its phenolic metabolites which are the active metabolites responsible for the elimination of dormant hypnozoites in the liver. Furthermore, these data suggested that
patients with impaired CYP2D6 activity caused by genetic
variation in the CYP2D6 gene may be at a higher risk of
relapse of P. vivax. However, a previous study by our
group has also found relapsing infections in patients with
normal CYP2D6 metabolism.14 It needs to be noted that
our patients have been treated with a combination of PQ
and CQ (per standard Thai guidelines). Thus, we are
speculating that genetic variation in other genes that contribute to PQ and CQ metabolism may also impact
a patient’s response to P. vivax treatment in Thai patients.
Moreover, in addition to drug-metabolizing enzymes,
transporters have been shown to affect PQ efﬁcacy.15,16
Sortica et al found that SLCO2B1, SLCO1A2 and
SLCO1B1 were associated with the clearance of P. vivax
in patients treated with PQ and CQ.16 The MRP transporter, for example, can be inhibited by quinoline
derivatives,17 and Hayeshi et al demonstrated inhibitory
effects of several antimalarial drugs to P-glycoprotein
(P-gp) mediated transport and reported that both, PQ and
chloroquine, inhibit P-gp.18
This study aimed to investigate genetic variation in
drug-metabolizing enzymes and drug transporters and

2
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their association with relapse in Thai patients treated
with a PQ/CQ combination regimen.

Materials and Methods
This exploratory investigation included 51 Thai patients
from a previous study.14 The study was approved by the
Internal Ethics Review Committee on Human Research of
the Faculty of Medicine, Ramathibodi Hospital, Mahidol
University, Thailand (MURA 2016/657) and conducted in
accordance with the Declaration of Helsinki. Brieﬂy,
symptomatic P. vivax patients from the Tha Song Yang
malaria clinic, Tak province, Thailand were recruited
from April 2014 to September 2015; all patients gave
written informed consent. Patients were diagnosed with
P. vivax infection and treated with 25 mg base/kg body
weight CQ over 3 days and 0.3 mg/kg PQ daily for 14
days. Finger-prick blood samples were collected before
treatment and at 1 and 2 weeks after enrollment, then
every 2 weeks for 6 months, then every 4 weeks until 9
months.14 Patients for the current study were selected
based on the availability of genomic DNA and clinical
data including recurrent status and date of follow up/
survival data.

Genes Analyzed with MassARRAY and
Real-Time PCR
DNA samples diluted to 10 ng/μL were genotyped using the
Sequenom MassARRAY® System (Agena Bioscience™, San
Diego, CA, USA). The panel consisted of pre-designed SNPs
and indels (referred to SNVs therein), and CNV assays that
target the most relevant variants in 11 important pharmacogenes. A total of 53 SNVs were interrogated and ﬁve assays
were utilized to determine CYP2D6 gene copy number variation (CNV) (Table 1). The iPLEX® PGx 68 Panel (Agena, San
Diego, CA) included drug transporters (ABCB1, SLCO1B1,
SULT4A1), Phase I enzymes (COMT, CYP1A2, CYP2B6,
CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5). The workﬂow consisted of ﬁve steps: PCR ampliﬁcation, primer extension or fragmentation, dispensed extension product onto
a SpectroCHIP® Array and MassARRAY MALDI-TOF
mass spectrometry. Automated software provided diplotype,
haplotype, and CNV calls in a single combined report. The
overall process was completed in less than 10 hrs.
An additional 21 SNVs of 10 genes including CYP2B6,
CYP3A4, ABCA1, ABCB1, ABCC2, ABCC4, ABCG2,
SLC25A40, SULT1A1, and UGT2B7 were genotyped
with commercially available TaqMan® Genotyping Assays
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Table 1 List of Genes and SNPs Detected by MassArray® and Taqman® RT-PCR
No.

Genes

Nucleotide Change

SNP ID

Alleles Detected

1

CYP1A2

g.-3860G>A, g.-163C>A, g.-729C>T,
g.3533G>A, g.558C>A

rs2069514, rs762551, rs12720461,
rs56107638, rs72547513

*1A,*1C,*1F,*1K,*7,*11

2

CYP2B6

c.983T>C, c.64C>T, c.516G>T, c.785A>G

rs28399499, rs8192709, rs3745274,
rs2279343

*2, *4, *6, *16, *18

3

CYP2C9

c.430C>T, c.1075A>C, c.1076T>C,
c.1080C>G, c.818delA, c.449G>A,

rs1799853, rs1057910, rs56165452,
rs28371686, rs9332131, rs7900194,

*2, *3, *4, *5, *6, *8, *11,
*12,*13, *15, *18, *25

c.1003C>T, c.1465C>T, c.269T>C,
c.485C>A

rs28371685, rs9332239, rs72558187,
rs72558190

c.681G>A, c.636G>A, c.1A>G, c.1297C>T,
c.395G>A, g.19294T>A, c.358T>C, g.-

rs4244285, rs4986893, rs28399504,
rs56337013, rs72552267, rs72558186,

806C>T

rs41291556, rs12248560

g.2850C>T, g.4180G>C, g.2549delA,

rs16947, rs1135840, rs35742686,

*1,*2,*3,*4,*6,*7,*8,*9,*10,

g.1846G>A, g.1707delT, g.2935A>C,

rs3892097, rs5030655, rs5030867,

*11,*12,*14A,*14B,*15,*17,

g.1758G>T, g.2615_2617delAAG, g.100C>T,
g.883G>C, g.124G>A, g.137_138insT,

rs5030865, rs5030656, rs1065852,
rs201377835, rs5030862, rs774671100,

*18,*19,*20,*29,*36,*41,*69
and *5 del

g.1023C>T, g.4125_4133dupGTGCCCACT,

rs28371706, hCV32407220, rs72549353,

g.2539_2542delAACT, g.1973_1974insG,
g.3183G>A, g.2988G>A, g.4155C>T

rs72549354, rs59421388, rs28371725,
rs28371735

4

5

CYP2C19

CYP2D6

*2,*3, *4, *5, *6, *7, *8, *17

6

CYP3A4

c.664T>C, c.566 T>C, g.15389C>T, c.392A>G, c.878T>C

rs55785340, rs4987161, rs35599367,
rs2740574, rs28371759

*1B, *2, *17, *18, *22

7

CYP3A5

g.27289C>A, g.6986A>G,
g.27131_27132insT

rs28365083, rs776746, rs41303343

*1A,*2,*3,*7, *10

8

ABCB1

c.1236C>T, c.2677G>T/A, c.3435C>T

rs1128503, rs2032582, rs1045642

*1, *2, *6

9

ABCA1

c.2649A>G, c.4760A>G

rs2066714, rs2230808

n/a

10

ABCC2

c.-24C>T, c.3972C>T, g.68231A>G

rs717620, rs3740066, rs3740065

*1A, *1C

11

ABCC4

c.912C>A, c.2269G>A

rs2274407, rs3765534

n/a

12

ABCG2

c.421C>A

rs2231142

n/a

13

SLCO1B1

g.37041T>C

rs4149056

*5

14

SULT1A1

c.638G>A

rs9282861

n/a

15

SULT4A1

*1113A>G

rs763120

n/a

16

SLC25A40

g.87868008C>G

rs10239908

n/a

17

COMT

c.322G>A

rs4680

n/a

18

UGT2B7

c.-161C>T, c.211G>T, c.372A>G, c.802C>T

rs7668258, rs12233719, rs28365063,

*1d, *2a, *3

hCV32449742
Notes: Allele deﬁnitions are according to the Pharmacogene Variation Consortium at www.PharmVar.org. SNV coordinates are provided either on the gDNA or cDNA
level based on which numbering is more commonly used in the literature. n/a, not available, ie SNP is not part of a star (*) allele deﬁnition. The reference SNP ID in bold are
in the MassArray iPLEX PGx68 panel; the CYP2D6 variants were deﬁned as M33388 reference sequence.

(Applied Biosystems™, Carlsbad, CA, USA) following manufacturer’s instructions. Details are provided in Table 1.
Allelic variants were designated according to the
Pharmacogene Variation Consortium (PharmVar) at www.
PharmVar.org.19,20

Pharmacogenomics and Personalized Medicine 2020:13

Activity scores (AS) were assigned as previously
described21 and applied in CPIC guidelines.22–25 To assess
the combined impact of CYP2D6 and CYP2C19 activity, we
assigned a composite AS, which is the sum of the AS assigned
to each gene.
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Statistical Analysis
Deviation from Hardy-Weinberg expectations was
assessed using an exact and chi-square test. SNV and
genotype frequencies were determined by direct counting. Linkage disequilibrium measures (r2) and haplotype
analysis were performed using Haploview version 4.2.26
Comparisons of SNV and genotype frequencies between
relapsing and non-relapsing patients were performed
using the χ2 test, odds ratio and 95% conﬁdence intervals were calculated as measurements of the strength of
association. The probability of signiﬁcant associations
was set at p<0.05. Relapse-free survival (RFS) was
estimated using the log-rank test and Kaplan–Meier
curves. The Cox proportional hazards model was conducted to assess the impact of candidate SNPs on
relapse of P. vivax. All statistical analyses were performed using STATA software version 14 (StataCorp
LP, TX, USA).

Results
Demographic Data
The average age of the 51 patients was 26.37 (min–max;
7–71) years with 32 (63%) males and 19 (37%) females.
There were four recurrent P. vivax infections, which occurred
between 8 and 32-weeks after the initial treatment, the
average time of follow-up was 7.7±1.7 months. The clinical
status of 45 patients was recorded for at least 6 months.

Association of Pharmacogene Variation
and Relapse
The call rate for SNV genotyping was 100% for both testing
platforms. Table 1 summarizes the genes and SNVs tested by
MassArray® and Taqman RT-PCR®. SNV and genotype frequencies in the relapsing and non-relapsing patients are provided in Tables 2 and 3, respectively. All SNVs were in HardyWeinberg equilibrium except CYP2D6 g.4180G>C and

Table 2 SNP Frequencies of Drug Metabolizing Genes Between Relapse and Non-Relapse Groups
Gene

Genotype

N (%)

Association Test

OR (95% CI)

p value

(N=51)
Relapse

Non-Relapse

(N=4)

(N=47)

CYP2C19
c.681G>A

G/G

28 (54.9)

0

28

–

0.052*

rs4244285

G/A
A/A

18 (35.3)
5 (9.8)

3
1

15
4

6.40 (0.61–66.76)
3.58 (0.30–42.97)

0.120
0.347

G/A+A/A

23 (45.1)

4

19

7.25 (0.79–66.84)

0.082

G
A

74 (72.6)
28 (27.5)

3
5

71
23

–
5.14 (0.90–35.01)

0.021**

UGT2B7
c.372A>G
rs28365063

A/A

30 (58.8)

1

29

–

0.177*

A/G

17 (33.3)

2

15

2.13 (0.27–16.63)

0.593

G/G
A/G+G/G

4 (7.8)
21 (41.2)

1
3

3
18

4.89 (0.38–62.46)
4.83 (0.47–50.09)

0.286
0.293

A

77 (75.5)

4

73

–

G

25 (24.5)

4

21

3.48 (0.59–20.08)

0.081

C/C
C/A

34 (66.7)
15 (29.4)

1
3

33
12

–
8.75 (0.83–92.32)

0.152*
0.071

A/A

2 (3.9)

0

2

3.07 (0.27–35.33)

0.379

C/A+A/A
C

18 (33.3)
83 (81.4)

3
5

14
78

7.07 (0.68–73.99)
–

0.102

A

19 (18.6)

3

16

2.93 (0.41–16.65)

0.153

ABCG2
c.421C>A
rs2231142

Notes: *Overall p value; **signiﬁcance (p<0.05); ref, reference was compared to others in the sub-analysis.
Abbreviations: N, number; OR, odds ratio; 95% CI, 95% conﬁdence interval.
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Table 3 Genotype Frequencies of Drug Metabolizing Genes
Between Relapse and Non-Relapse Groups
Gene

Genotype

N (%)

Relapse
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p value

Association Test

Table 3 (Continued).
Gene

Genotype

N (%)

Association Test
Relapse

Non-

CYP1A2

(N=4)

(N=47)

*1A/*1A

2 (3.9)

0

2

*1A/*1F

16 (31.4)

1

15

*1A/*1L or

6 (11.8)

1

5

0.608*

CYP3A5

*1C/*1F
8 (15.7)

0

8

*1F/*1L

14 (27.5)

1

13

*1L/*1L

5 (9.8)

1

4

4

45

0.379

0.180*

SLCO1B1

others
CYP2B6

CYP2C9

CYP2C19

*1/*1

15 (29.4)

1

14

*1/*2

1 (2.0)

0

1

*1/*4

2 (3.9)

1

1

*1/*6

21 (41.2)

1

20

*2/*6

1 (2.0)

0

1

*4/*6

3 (5.9)

1

2

*6/*6

8 (15.7)

0

8

*1/*1

47 (92.2)

4

43

*1/*3

3 (5.9)

0

3

*3/*3

1 (2.0)

0

1

*1/*1

23 (45.1)

0

23

*1/*2

17 (33.3)

3

14

*1/*3

4 (7.8)

0

4

*1/*5

1 (2.0)

0

1

*2/*2

5 (9.8)

1

4

*2/*3

1 (2.0)

0

1

*1/*2+*2/

22 (43.1)

4

18

0.075*

*1/*1

5 (9.8)

0

5

0.937*

*1/*2

4 (7.8)

0

4

*1/*5

4 (7.8)

1

3

*1/*10

4 (7.8)

0

4

*1/*41

1 (2.0)

0

1

*2/*2

6 (11.8)

0

6

*2/*10

11 (21.6)

2

9

*2/*41

3 (5.9)

0

3

*4/*10

1 (2.0)

0

1

*5/*5

1 (2.0)

0

1

*5/*10

1 (2.0)

0

1

*10/*10

8 (15.7)

1

7

*10/*41

2 (3.9)

0

2

*1/*1

49 (96.1)

4

45

*1/*1B

2 (3.9)

0

2

1.000*

0.211*

*2 vs
others
CYP2D6

CYP3A4

0.379*

(Continued)

Pharmacogenomics and Personalized Medicine 2020:13

(N=51)

(N=4)

(N=47)

*1A/*1A

4 (7.8)

1

3

*1A/*3

19 (37.3)

1

18

*3/*3

28 (54.9)

2

26

*1A/*3+*3/

47 (92.2)

3

44

0.286

*1/*1

47 (92.2)

3

44

0.286*

*1/*5

4 (7.8)

1

3

Note: *Overall p-value.
Abbreviations: OR, odds ratio; 95% CI, 95% conﬁdence interval.

ABCA1 c.4760A>G (p<0.05) which were excluded from subsequent analyses. Nine SNVs in nine genes had minor allele
frequency (MAF) of less than 5% (Table S1). The frequencies
of the most common genotypes are shown in Table 3 which
were CYP1A2*1A/*1F (31.4%), CYP2B6*1/*6 (41.2%),
CYP2C9*1/*3 (5.9%), CYP2C19*1/*2 (33.3%), CYP2D6*2/
*10 (21.6%), CYP3A4*1/*1B (3.9%), CYP3A5*3/*3 (54.9%),
and SLCO1B1*1/*5 (7.8%). In addition, frequencies for 0, 1,
2, 3 and 4 CYP2D6 gene copies were 1.96% (n=1), 9.80%
(n=5), 45.10% (n=23), 41.18% (n=21), and 1.96% (n=1),
respectively. The CYP2D6 CNV status and genotype of the
four relapsed patients were three copies (two patients with
a CYP2D6*2/*10 and 1 patient with a CYP2D6*10/*10 genotype) and one copy (one patient genotyped as CYP2D6*1/
*5). None of these genotypes, or any other genotypes, revealed
statistically signiﬁcant association between relapse and nonrelapse (Tables 3 and S2).
The genotype frequencies of the majority of drugmetabolizing enzyme and transporter genes of the relapsing
patients were similar with those previously described for
Thai. Frequencies for the candidate genes including
CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP1A2 were
not signiﬁcantly different among non-relapsing and relapsing patients (p>0.05). As shown in Table 3 there was
a trend, however, for a signiﬁcant association between
CYP2C19 c.681G>A, and relapse (G/A+A/A genotypes vs
G/G genotype; OR=7.25, 95% CI; 0.79–66.84, p=0.082).
Furthermore, the c.681A SNV deﬁning the non-functional
CYP2C19*2 allele was signiﬁcantly more common than the
c.681G allele in relapse versus non-relapse patients

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

0.492*

*3

*1F/*1F

*1A/*1A vs

NonRelapse

Relapse
(N=51)

p value

5

Dovepress

Pharmacogenomics and Personalized Medicine downloaded from https://www.dovepress.com/ by 69.247.206.119 on 10-Oct-2020
For personal use only.

Chamnanphon et al

(OR=5.14, 95% CI; 0.90–35.01, p=0.021). Moreover, the
ABCG2 c.421C>A transporter SNV had a higher odds ratio,
although this did not reach statistical signiﬁcance
(OR=8.75, 95% CI; 0.83–92.32, p=0.071). Lastly, we also
explored the relationship between a composite AS for
CYP2D6 + CYP2C19 and PQ response. A composite AS,
however, was not signiﬁcantly different (p=0.09)
(Table S3).

Also, as shown in Figure 1C and D, a sub-analysis of
CYP2D6 copy number variation revealed signiﬁcantly different RFS rates between 1 and 2 gene copies (p=0.007) and
between 2 and 3 gene copies (p=0.065), respectively. There
was no statistical difference in RFS rates among groups for
any of the other variable factors (Table S4).

Survival Analysis

Relapse-Free Survival Rate by Univariate
and Multivariate Analysis

RFS was calculated from enrollment date to the time of
P. vivax relapse. The effect of genetic variation in pharmacogenes on RFS was investigated by grouping patients by SNVs
and genotype. Kaplan–Meier analysis revealed no statistically
signiﬁcant differences in RFS rates for most of the variable
factors. However, a trend toward statistical signiﬁcance of
RFS rates was observed for patients carrying the CYP2C19*2
allele (c.681G>A) (Log-rank test; p=0.077, Figure 1A), and
ABCG2 c.421C>A (Log-rank test; p=0.099, Figure 1B).

Cox proportional hazards analysis was used for the determination of univariate and multivariate association analysis of the SNVs with RFS. In multivariate analyses, there
was no signiﬁcant difference in RFS rates between SNVs,
genotype or other variables (Table 4). However, a subanalysis showed that CYP1A2 g.-163C>A, CYP2C19*2
(c.681G>A), CYP2D6 copy number, ABCA1 c.2649A>G,
ABCB1 c.1236C>T, ABCC2 g.68231A>G, ABCG2 c.42
1C>A, and SLCO1B1 g.37041T>C had statistically

A

B

Log rank test; P = 0.077

C

Log rank test; P = 0.099

D

Log rank test; P = 0.007

Log rank test; P = 0.065

Figure 1 Kaplan–Meier estimates of relapse-free survival according to (A) CYP2C19 c.681G>A genotype, (B) ABCG2 c.421C>A genotype, (C) CYP2D6 copy number
variation (CNV) 1 vs 2 gene copies, (D) CYP2D6 CNV 2 vs 3 gene copies.
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Table 4 Univariate and Multivariate Analysis of the Effects of Different Variables on P. vivax Relapse Outcome
Variable Factors

Univariate Analysis

Multivariate Analysis

HR (95% CI)

p value

HR (95% CI)

p value

*1A/*1A
*1A/*1F

Ref.
1.66e+09

–

–
–

–
–

*1A/*1L or *1C/*1F

4.15e+09 (2.60e+08 – 6.64e+10)

<0.001

–

–

*1F/*1F
*1F/*1L

–
1.72+09 (1.08 e+08 – 2.75e+10)

1.000
<0.001

–
–

–
–

*1L/*1L

4.54+09 (2.84e+08 – 7.28e+10)

<0.001

–

–

1.46 (0.08–26.25)

0.799*

–
13.85

–
1.000

Pharmacogenomics and Personalized Medicine downloaded from https://www.dovepress.com/ by 69.247.206.119 on 10-Oct-2020
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CYP1A2 genotype

CYP1A2 g.-163C>A
C/C

Ref.

C/A
A/A

2.30e+08
1.68e+08 (2.38e+07-1.19e+09)

CYP2C19 genotype
*1/*1

<0.001

–

–

*1/*2

1.69e+10 (1.76e+09-1.63e+11)

<0.001

–

–

*1/*3
*1/*5

1.12e-07
1.12e-07

1.000
1.000

–
–

–
–

*2/*2

1.95e+10

-

–

–

*2/*3

1.12e-07

1.000

–

–

18.64 (0.79–439.28)

0.070*

CYP2C19 c.681G>A
G/G

ref.

Ref.

G/A

1.52e+10 (1.58e+09-1.46e+11)

<0.001

4.24e+37

0.998

A/A
G/G vs A/A

8.08e+17

1.000

–
–

–
–

1.31 (0.60–2.89)
–

0.505*
–

CYP2D6 genotype
*1/*1

Ref.

*1/*10

8.32e-07

1.000

–

–

*1/*2
*1/*41

8.32e-07
8.32e-07

1.000
1.000

–
–

–
–

*1/*5

4.78e+10

-

–

–

*10/*10
*10/*4

1.26e+10 (6.95e+08-2.29e+11)
8.32e-07

<0.001
1.000

1.94e-19
–

–
–

*10/*41

8.32e-07

1.000

–

–

*10/*5
*2/*10

8.32e-07
1.74e+10 (1.37e+09-2.22e+11)

1.000
<0.001

–
8.97e-38

–
–

*2/*2

7.85e-07

1.000

–

–

*2/*41
*5/*5

8.32e-07
8.32e-07

1.000
1.000

–
–

–
–

CYP2D6 CNV

1.36 (0.32–5.705)

0.678

–

CNV: 2 copy vs 1 copy

3.55e-18

-

CNV: 2 copy vs 3 copy

2.99e+15

-

ABCB1 c.1236C>T
C/C

Ref.

C/T

5.10e+08 (7.16e+07-3.64e+09)

T/T

1.60e+08

<0.001

0.150 (0.01–3.233)
–

0.225*

0.002

1.000

–

-

(Continued)
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Table 4 (Continued).
Variable Factors

Univariate Analysis

Multivariate Analysis
p value
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HR (95% CI)
ABCA1 c.2649A>G
A/A

p value

4.30 (0.18–101.12)
–

0.365*

A/G

1.64e+09 (1.71e+08-1.58e+10)

<0.001

1.28e+08

0.999

G/G

1.46e+09

-

–

-

30.90 (0.13–7451.06)

0.220*

0.186

–
1.07e+32

0.997

ABCC2 g.68231A>G
A/A
A/G

Ref.
4.61 (0.48–44.30)

ABCG2 c.421C>A
C/C

Ref.

9.28 (0.15–557.93)
–

0.287*

C/A

7.57 (0.79–72.86)

0.080

1.08e+15

–

A/A
C/C vs A/A

8.69e-16
2.40e-08

1.000
1.000

–

–

120.68 (0.14–102070.4)
–

0.163*
–

2.94e+46

–

SLCO1B1 g.37041T>C
T/T
T/C

ref.
5.03 (0.52–48.80)

0.163

Notes: Reference was compared to others in the sub-analysis; *overall p-value; vs, versus.
Abbreviations: HR, hazards ratio; 95% CI, 95% conﬁdence interval; ref, reference.

different RFS rates (p<0.05). However, there were no
differences in RFS rates in the multivariate analysis.

Discussion
This study investigated the frequencies of sequence variations in eleven drug-metabolizing enzymes contributing to
phase I (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6,
CYP3A4 and CYP3A5) and Phase II (COMT, SULT1A1,
SULT1A4 and UGT2B7) metabolism of PQ and CQ as well
as seven drug transporter genes (ABCB1, ABCA1, ABCC2,
ABCC4, ABCG2, SLCO1B1 and SLC25A40) in 51 Thai
patients infected with P. vivax. Although the inﬂuence of
drug-metabolizing enzymes and drug transporters on the
efﬁcacy of PQ treatment on P. vivax infection has been
studied,7,14,16,27 their contribution to relapse is still unclear.
In vitro studies have shown that several phase I and II
enzymes strongly relate with PQ metabolisms including
CYP450 1A2, 2C19, 2C9, 2D6, 3A4, FMO-1, 3, 5 and
MAO-A and B4–6 and CYP2C8, CYP3A4, and CYP2D6
with CQ metabolism.11 Therefore, genetic variation in these
enzymes likely impacts the pharmacokinetics of both drugs
to various degrees. However, to the best of our knowledge,
no studies have assessed the association of pharmacogene
variation and relapse other than CYP2D6 after treatment with
PQ or a combination of PQ and CQ. It has been reported that
CYP2D6 metabolizer status inﬂuences PQ efﬁcacy.7,14
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Bennette et al7 ﬁrst described that two study participants
(6%), one PM with a CYP2D6*5/*6 genotype and one IM
with a CYP2D6*4/*41 genotype signifying considerable
decreased activity, had multiple relapses of P. vivax while
participants with genotypes predicting normal metabolizer
(NM) status were not found to relapse. Furthermore, relapse
patients had signiﬁcantly higher amounts of the parent drug
PQ AUCinf (p<0.001) compared with non-relapse patients.
These data support their hypothesis that the highly polymorphic CYP2D6 gene contributed to the failure to bioactivate PQ to its active phenol metabolites that are responsible
for killing hypnozoites. The clinical study by Nelwan et al28
demonstrated high efﬁcacy of PQ against P. vivax relapse in
Indonesia although relatively high relapse rates of 14% were
observed among treatment groups while 75% of the patients
in the control arm relapsed. Unfortunately, CYP2D6 genotyping was not performed in this study. Subsequent studies
by Baird et al29 reported that decreased CYP2D6 activity was
associated with increased risk of therapeutic failure. These
authors reported that patients with CYP2D6 activity scores of
1.0 or less had a higher risk of relapse compared to patients
with scores >1.0 (OR=9.4, P=0.001). Another study conducted by Spring et al30 conﬁrmed that subjects with
CYP2D6 IM or PM phenotypes have reduced PQ metabolism compared to those with an NM phenotype. In contrast,
Chen et al31 found that CYP2D6 phenotype or activity scores
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were not signiﬁcantly different between their relapse and
non-relapse groups.
One explanation of why the present study did not ﬁnd
a relationship between CYP2D6 genotype or metabolizer
status and PQ response may be due to the coadministration of CQ. Based on in-vitro studies, CQ is
metabolized into N-desethylchloroquine by CYP2C8,
CYP3A4, and CYP2D6. CYP2C8 and CYP3A4 constitute
low-afﬁnity, high-capacity systems while CYP2D6 may
play a more important role at low CQ concentrations
contributing to low-afﬁnity, high-capacity systems11 of
metabolism explaining why CQ may cause modest inhibition of CYP2D6 activity in humans when co-administered
with debrisoquine.32 Thus, it cannot be excluded that CQ
inhibits CYP2D6 activity to a certain extent and thereby
reduce the enzyme’s capacity to efﬁciently bioactivate PQ.
Furthermore, our study is limited by the small number of
relapsed patients decreasing statistical power; small number size may also be a source of misclassiﬁcation bias.
Therefore, the ﬁndings of this study need to be viewed as
preliminary. Although the patients were extensively genotyped for CYP2D6 and CNVs, we cannot exclude the
possibility that the relapsing patients possess additional
rare, or novel sequence variants and/or structural variants
that decrease or obliterate CYP2D6 activity and drug
response.33 We also like to stress that a lack of hypnozoites in the controls at the time of treatment initiation
with PQ may have misclassiﬁed these patients as treatment
successes, in fact over 22% of the relapse controls in
clinical trial treated without PQ did not relapse.28,34
Thus, the recruitment of controls lacking hypnozoites
would bias the statistical analysis for patients with
decreased or no CYP2D6 activity. In addition, yet another
explanation needs to be entertained, ie hypnozoite resistance to PQ,35,36 which may occur especially in some
relapsing patients with normal and ultrarapid CYP2D6
activity.
Finally, there is sparse information, regarding the level
of activity towards PQ that is conferred by alleles classiﬁed
as decreased function alleles. For example, the CYP2D6*10
allele, which is the most common decreased function allele
in Asians and has a frequency of 34.31% in our population,
appears to have considerably less activity towards tamoxifen compared to the probe drug dextromethorphan. This
observation triggered speciﬁc recommendations in the
tamoxifen/CYP2D6 drug/gene pair guideline recently published by the Clinical Pharmacogenetic Implementation
Consortium (CPIC) for patients carrying the CYP2D6*10
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allele.37 It is not inconceivable that CYP2D6*10 and other
decreased function alleles metabolize PQ and/or CQ at rates
that are lower than expected from their current function
classiﬁcations (see variation and functionality tables available at https://www.pharmgkb.org/page/pgxGeneRef) and
put carriers at risk of relapse due to the failure of producing
sufﬁciently high levels of exposure to the metabolites that
are responsible for eradicating hypnozoites.
Regarding CYP2C19, the non-functional CYP2C19*2
allele (c.681G>A; rs4244285) was found at a statistically signiﬁcantly higher allele frequency among the relapse patients
(62.5%, 5/8) compared with 24.5% (23/94) among the nonrelapse patients. The minor allele frequency was 26% in our
study cohort making this a rather common non-functional
allele in the Thai population.38–40 Although Pybus et al4
describe CYP2C19 as a minor contributing pathway for PQ
metabolisms into its active metabolites, its contribution may
assume a more prominent role in patients with compromised
CYP2D6 activity. This is exempliﬁed by one of our relapsing
patients who was genotyped as CYP2D6*2/*10 and
CYP2C19*2/*2. A composite activity score taking CYP2D6
and CYP2C19 into account may therefore be more informative to predict the risk of P. vivax relapse than either of these
genes alone as suggested by our data (Table S3). The use of
a combined metabolism index has been proposed previously
by Villagra et al41 concluding that a
combinatory approach represents an improvement over the
current gene-by-gene reporting by providing greater scope
while still allowing for the resolution of a single-gene
index when needed, especially when drugs are metabolized or activated by multiple pathways

which is clearly the case for the treatment with a combined
PQ/CQ regimen.
This study is the ﬁrst to examine the impact of variants
in the ABCG2 efﬂux drug transporter on PQ response. This
gene, also known as the Breast Cancer Resistance Protein
(BRCP) is expressed in intestine, liver, kidney, placenta,
and brain capillaries and plays an important role in the
absorption, distribution, and removal of drugs across the
cell membrane.42 This transporter is believed to play
a protective role by blocking drug absorption at the apical
membrane of the intestine and the blood–brain barrier
among other sites. At the apical membranes of the liver
and kidney, it facilitates efﬂux of xenobiotics lowering
intracellular drug levels.43,44 Interestingly, although not
signiﬁcant, more subjects were heterozygous for ABCG2
c.421C/A (rs2231142) than homozygous for the reference
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allele (C/C; p=0.071). The mechanism of this variant,
however, is unknown. ABCB1 is a member of the superfamily of ATP-binding cassette (ABC) transporters like
ABCG2. Sortica et al16 reported that ABCB1 (MDR1,
P-gp) T/nonG/T haplotype carriers (3435C>T, 2677G>A/
T and 1236C>T) were associated with lower parasitemia
clearance rates over treatment time in a model adjusted for
other clinical factors; however, there was no longer statistically signiﬁcant difference after false discovery rate analysis. The absence of an association between relapse and
ABCG2 in this study may be due to the small number of
relapse patients and/or inhibitory effects of CQ that seems
to be an inhibitor to some ABC transporters.18 Two previous studies suggested that MAO-A/B enzyme activity
relates with PQ metabolism,4,6 however, we did not test the
relationships between MAO variants and RFS rates.
In addition to the study limitations mentioned above, we
acknowledge that adherence was assessed retrospectively
by reviewing a data registry. Although a risk of P. vivax
reinfection could not be ruled out, the risk in our region is
less than 5% during the 42-day period, assuming that most
P. vivax infection recurrences were indeed relapses,45,46 and
parasite genotyping for two polymorphic markers suggested
a high probability of late relapsing infections in these
volunteers.14 Nonetheless, further work is warranted to
assess the impact of CYP2D6, CYP2C19, ABCG2 and
potentially other drug-metabolizing enzymes and transporters on relapse in larger patient populations.

Conclusion
Although we did not ﬁnd an association between CYP2D6
genotype and relapse, sequence variations in other pharmacogenes emerged as additional candidate genes that
may contribute to variability in PQ/CQ drug response.
These ﬁndings warrant further investigation, however, in
larger study populations.

Abbreviations
PQ, Primaquine; CQ, Chloroquine; CYP, Cytochrome P450;
ABCB1, ATP-Binding Cassette Subfamily B Member 1;
ABCC2, ATP-Binding Cassette Subfamily C Member 2;
MAO, Monoamine oxidase; ABCG2, ATP-Binding Cassette
Subfamily G Member 2; COMT, catechol-O-methyltransferase; SLCO1B1, solute carrier organic anion transporter
family member 1B1; SULT4A1, Sulfotransferase Family 4A
Member 1; SLC25A40, Solute Carrier Family 25 Member 40,
UGT2B7, UDP Glucuronosyltransferase Family 2 Member
B7; RFS, Relapse-free survival; CPQ, Carboxy primaquine;
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